KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Deferred Tax (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Long-Term Deferred Tax for 7 consecutive years, with $11.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 1014.8% to $11.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.8 million, a 1014.8% increase, with the full-year FY2024 number at $9.7 million, up 1105.24% from a year prior.
  • Long-Term Deferred Tax was $11.8 million for Q3 2025 at Xenon Pharmaceuticals, up from $11.0 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $11.8 million in Q3 2025 to a low of $207000.0 in Q1 2022.
  • A 5-year average of $2.7 million and a median of $544000.0 in 2021 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: tumbled 59.73% in 2022, then surged 2619.75% in 2025.
  • Xenon Pharmaceuticals' Long-Term Deferred Tax stood at $465000.0 in 2021, then rose by 9.46% to $509000.0 in 2022, then skyrocketed by 57.56% to $802000.0 in 2023, then soared by 1105.24% to $9.7 million in 2024, then grew by 21.56% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Long-Term Deferred Tax are $11.8 million (Q3 2025), $11.0 million (Q2 2025), and $10.9 million (Q1 2025).